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ABSTRACT
CD93 is a transmembrane glycoprotein predominantly expressed in endothelial 
cells. Although CD93 displays proangiogenic activity, its molecular function in 
angiogenesis still needs to be clarified. To get molecular insight into the biological role 
of CD93 in the endothelium, we performed proteomic analyses to examine changes 
in the protein profile of endothelial cells after CD93 silencing. Among differentially 
expressed proteins, we identified dystroglycan, a laminin-binding protein involved 
in angiogenesis, whose expression is increased in vascular endothelial cells within 
malignant tumors. Using immunofluorescence, FRET, and proximity ligation analyses, 
we observed a close interaction between CD93 and β-dystroglycan. Moreover, silencing 
experiments showed that CD93 and dystroglycan promoted endothelial cell migration 
and organization into capillary-like structures. CD93 proved to be phosphorylated 
on tyrosine 628 and 644 following cell adhesion on laminin through dystroglycan. 
This phosphorylation was shown to be necessary for a proper endothelial migratory 
phenotype. Moreover, we showed that during cell spreading phosphorylated CD93 
recruited the signaling protein Cbl, which in turn was phosphorylated on tyrosine 
774. Altogether, our results identify a new signaling pathway which is activated 
by the cooperation between CD93 and dystroglycan and involved in the control of 
endothelial cell function. 
INTRODUCTION
Endothelial cell (EC) migration is a complex 
process fundamental to angiogenesis. During cell 
migration, the integration of several signals, largely 
provided by extracellular matrix (ECM), is essential to 
activate intracellular signaling pathways that affect cell 
shape, polarity, and cytoskeletal remodeling [1]. Several 
classes of cell surface proteins have been demonstrated 
to play important roles in the regulation of EC migration 
and blood vessel formation [2]. In addition to integrins, a 
family of adhesion receptors responsible for high affinity 
adhesion to ECM, other surface molecules can bind 
ECM components and induce signaling [3]. Therefore, 
the discovery of alternative adhesion mechanisms and 
their contribution to angiogenesis may shed light on the 
molecular machinery of blood vessel formation.
CD93, also known as the complement component 
C1q receptor (C1qRp), is a cell surface glycoprotein, 
which together with endosialin and thrombomodulin 
constitute a small family of transmembrane proteins with 
similar extracellular domains [4]. In our previous report 
[5], we demonstrated that CD93 activated angiogenesis 
by promoting adhesion of ECs. Along with our findings, 
a good amount of evidence suggests that CD93 plays a 
role in the endothelium. Indeed, its predominant site 
of expression is the vascular endothelium and, in the 
developing embryo, the mouse homologue of CD93 is 
expressed especially during the remodeling of blood 
vessels [6, 7]. Furthermore, the surface domains of CD93, 
which are susceptible to protein ectodomain cleavage, act 
as angiogenic growth factors [8]. 
Dystroglycan (DG) is an important ECM adhesion 
molecule first isolated from skeletal muscle as a 
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component of the dystrophin glycoprotein complex 
[9, 10]. DG consists of two non-covalently associated 
subunits (α and β) encoded from a single gene and binds 
to several ECM ligands [11]. DG is widely expressed 
and, even though its role in the conservation of muscle 
integrity has been well established, it has a more general 
function in cell adhesion and signaling that is not yet fully 
understood [12]. Indeed, DG is expressed in ECs and 
involved in cell adhesion to ECM [13–15]. Moreover, it 
was observed that β-DG was needed for EC migration on 
laminin matrix and its expression was downregulated in 
quiescent and differentiated ECs. On the contrary, β-DG 
expression level was found to be high in ECs of malignant 
tumors, hyperplastic and inflamed tissues, where ECs were 
assembling new blood vessels [14, 16]. Although these 
observations strengthen the involvement of CD93 and DG 
in angiogenesis, their molecular mechanisms of action in 
the endothelium are largely unknown.
In the present study, we identify cooperative 
interactions between CD93 and DG and demonstrate that 
this relationship promotes EC migration, survival and 
tube formation. We show that phosphorylation of CD93 
through DG engagement is instrumental in EC migration 
and differentiation, unveiling new signaling mechanisms 
that govern EC migration in the context of angiogenesis. 
RESULTS
CD93 and β-DG exhibit a close association in ECs
To get molecular insight into the characterization 
of the biological role of CD93 in the endothelium, we 
performed proteomic analyses to examine changes in the 
protein profile of human umbilical vein ECs (HUVEC) 
after CD93 knockdown by lentiviral expression of small 
hairpin RNAs (Figure S1). By comparing 2-dimensional 
electrophoresis (2-DE) maps obtained from ECs following 
manipulation of CD93 expression and cells expressing an 
unrelated shRNA, we identified 52 differentially expressed 
proteins (data not shown). Among these proteins, the cell 
adhesion molecule β-DG appeared upregulated (Figure 1A). 
This upregulation was validated by Western blotting analysis, 
which showed that in ECs, β-DG levels increased following 
CD93 knockdown (Figure 1B and 1C). Since in the cellular 
machinery of adhesion, a specific cell adhesion molecule 
may influence the activity and/or expression of another type 
of molecule [17–19], we further investigated the effects of 
DG silencing on CD93 protein levels. β-DG protein levels 
were decreased in HUVEC by the use of two lentiviral 
constructs expressing two independent DG shRNAs (clones 
C7 and C10). HUVEC infected with lentiviruses expressing 
either DG shRNA showed reduced β-DG but increased 
CD93 protein levels as compared to non-infected cells 
or cells infected with a lentivirus expressing an unrelated 
shRNA (Figure 1D and 1E), suggesting the existence of a 
bidirectional connection between CD93 and β-DG in ECs. 
To assess the hypothesis that CD93 and DG can 
interact together, double immunofluorescence staining and 
colocalization analysis of fully spread ECs showed that 
CD93 and β-DG shared a similar cellular labeling pattern 
and displayed significant colocalization at cell surface 
(Figure 2A). To verify whether CD93 and β-DG interacted 
directly we transiently transfected CD93-YFP and β-DG-
CFP into HUVEC and performed fluorescence resonance 
energy transfer (FRET) analysis. Transfected cells were 
initially analyzed by immunofluorescence using anti-CD93 
and anti-β-DG antibodies to confirm that the exogenously 
expressed proteins were indeed CD93 and β-DG (Figure S2 
and [5]). Next, we investigated CD93-YFP and β-DG-CFP 
cellular localization. In ECs adhering to the substrate, both 
tagged proteins showed a high degree of colocalization 
at the cell membrane and within intracellular vesicles 
(Figure 2B). Afterward, in cells transfected with both 
expression plasmids, photobleaching of the acceptor 
fluorophor (CD93-YFP) increased the fluorescence 
intensity of the donor (β-DG-CFP) (Figure 2C), indicating 
that the two fluorophores were in close proximity. After 
photobleaching, additional ROIs, including more discrete 
cell regions both inside and outside the bleached area, were 
chosen for a more accurate evaluation of FRET efficiency 
and background (Figure S3).
To assess if the interaction was direct as suggested 
by the FRET analyses, we performed a proximity ligation 
assay, which allows in situ localization of protein-
protein interactions at single-molecule resolution [20]. 
In exponentially growing ECs treated simultaneously 
with anti-CD93 and anti-β-DG primary antibodies, we 
observed the presence of fluorescent spots due to localized 
amplification of the probes bound in close proximity, 
whereas we did not observe any fluorescent signal when 
the primary antibodies were used alone (Figure 2D). 
Altogether, these results support the idea that in ECs CD93 
and β-DG are in close association.
CD93 or DG silencing impairs EC function
Previously, we demonstrated that proliferation, 
migration, and differentiation of human primary ECs 
were strongly decreased when the function of CD93 was 
neutralized [5]. Therefore, to assess whether CD93/β-DG 
convergence had functional consequences in ECs during 
angiogenesis, we first analyzed changes in cell number 
and viability in DG-silenced HUVEC at different time 
points of cell growth. ECs infected with lentiviruses 
expressing either DG shRNA showed a decrease in cell 
viability, as well as in cell number when compared to 
cells not infected or infected with an unrelated shRNA 
(Figure 3A and 3B). Importantly, the same extent of 
reduction in cell number and viability was observed also 
in CD93-silenced cells (Figure 3A and 3B). Moreover, 
analysis of cell migration showed that ECs silenced for 
DG exhibited a significant decrease in VEGF-stimulated 
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migration compared to control cells (Figure 3C), similar 
to that previously observed in CD93-silenced ECs [5]. 
Since in a wound healing assay the open gap is sealed 
through a combination of proliferation and migration 
[21], we asked whether CD93- or DG-silenced cells were 
able to heal a wound. As expected, HUVEC expressing 
either CD93 or DG shRNAs were unable to heal the 
wound in 8 hours of cell growth, in contrast to cells 
infected with an unrelated shRNA that filled the open 
gap in the same period of time (Figure 3D and 3E). 
Interestingly, proliferation and migration of CD93/DG 
double-silenced cells decreased in comparison to control 
cells and the extent of reduction was equal or higher to 
that observed for individual-silenced cells (Figure S4), 
suggesting that CD93 and β-DG exert unidirectional 
effects on downstream effector(s). Finally, we performed 
a tube formation assay on Matrigel, a substrate that 
allows attachment and differentiation of ECs. HUVEC 
infected with an unrelated shRNA formed a complete 
network of tubular-like structures, whereas only a small 
number of tubes were formed by DG-silenced ECs 
(Figure 3F and 3G). The same impaired tubulogenesis 
was previously described for HUVEC grown on Matrigel 
in the presence of an anti-CD93 neutralizing antibody [5].
CD93 and DG crosstalk
Whilst DG is known to bind different ECM 
molecules [11], no ECM ligands have been identified for 
CD93 so far. To measure the direct binding of CD93 with 
ECM proteins, we produced soluble CD93 extracellular 
domain recombinant proteins and applied them to ELISA 
plates coated with different purified ECM proteins. No 
interactions were detected between CD93 and fibronectin, 
vitronectin, laminin, type I, or type IV collagen (Figure S5). 
DG engagement by laminin results in the 
phosphorylation of the cytoplasmic domain of β-DG 
[22]. Since β-DG interacts with several proteins to 
transduce extracellular signals into cells and several 
cell adhesion processes are activated by tyrosine 
phosphorylation, we asked whether following cell 
adhesion the CD93/β-DG interaction could result in 
CD93 phosphorylation. To address this issue, we used 
computational analysis and identified two putative 
phosphorylation sites at the level of tyrosine 628 and 644 
of the human sequence (Figure 4A). Interestingly, these 
tyrosine residues were found to be phosphorylated in a 
phosphoproteomic analysis of lung tumors [23]. Next, 
ECs were plated and allowed to spread onto laminin 
Figure 1: In ECs DG and CD93 silencing reveals adaptive changes in expression of both proteins. (A) HUVEC were 
infected with lentiviral vectors expressing unrelated (unr) or CD93 shRNAs (clones 85 and 86). Total cell lysates were obtained from 
exponentially growing cells and subjected to comparative proteomic analysis. Expanded views from the 2-DE gels show the increased 
expression pattern of β-DG in CD93-silenced cells compared to cells expressing an unrelated shRNA. Arrows indicate the experimental 
coordinates (pI and Mr) of the spot identified as β-DG by mass spectrometry. (B) HUVEC were infected as in A. Cell extracts were analyzed 
by Western blotting using anti-CD93 and anti-β-DG antibodies. Anti-β-actin antibodies were used to confirm equal protein loading. Not 
infected cells (HUVEC). (C) Quantitative analysis of β-DG protein levels from independent experiments performed as in B. Protein levels 
were quantified by densitometric scanning and the values, normalized to β-actin protein levels, were averaged and expressed as arbitrary 
units. (D) ECs were infected with lentiviral vectors expressing unrelated (unr) or DG shRNAs (clones C7 and C10). Cell extracts were 
analyzed by Western blotting as in B. (E) Quantitative analysis of CD93 protein levels performed as in D, normalized to β-actin protein 
levels, and expressed as arbitrary units. Representative images from a triplicate set are shown and data represent the means ± SD of three 
independent experiments.
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Figure 2: Direct association between CD93 and β-DG in ECs. (A) HUVEC, plated onto laminin-coated glass coverslips, were 
fixed during the late phase of spreading and analyzed by immunofluorescence using anti-β-DG and anti-CD93 antibodies. Differential 
interference contrast (DIC), overlay of stained cells, and white dot colocalization images are shown. Plot shows quantification (using 
Manders’ coefficient) of CD93 colocalization with β-DG at the cell margin (c.m.) and in whole cells (w.c.) (mean ± SD; cells = 21; 
n = 3). Scale bar, 12 μm. In the inset white dots show CD93 and β-DG colocalization at the cell margin. Scale bar of the inset is 3 μm. 
(B) CD93-YFP and β-DG-CFP were cotransfected into ECs. Fully spread cells on laminin-coated surfaces were fixed and subjected to 
immunofluorescence. Immunofluorescence shows CD93 and β-DG colocalization both at the plasma membrane and within intracellular 
vesicles. Scale bar, 8 μm. (C) Cells treated as in B were subjected to FRET analyses. The mean value of the FRET efficiency between 
acceptor (CD93-YFP) and donor (β-DG-CFP) was 9.11 ± 0.84%, after subtraction of the background. FRET data represent the means ± SD 
of three independent experiments, carried out on different days and with different cell preparations. (D) Representative confocal images 
of CD93/β-DG protein interaction detected in situ by Duolink stain. HUVEC exponentially growing on laminin-coated surfaces were 
fixed and treated at the same time with mouse anti-CD93 and rabbit anti-β-DG antibodies (CD93-β-DG). Close proximity of the primary 
antibodies was revealed by localized amplification. Protein-protein interactions were visualized as individual spots by red fluorescence. 
Background was assayed by removing one of the two primary antibodies from the reaction (anti-β-DG antibodies removed, neg. contr. 
CD93; anti-CD93 removed, neg. contr. β-DG). DIC images of stained cells are shown. The corresponding cell boundary is indicated by 
white dotted lines. Experiment was performed three times. Scale bars represent 18 μm.
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Figure 3: CD93 or DG knockdown impairs EC function. HUVEC were infected with a lentiviral vector expressing unrelated 
(unr), or CD93 (clones 85 or 86), or DG (clones C7 or C10) shRNAs. Not infected ECs were also analyzed (HUVEC). (A) Cell viability 
assay performed at the indicated time points on infected HUVEC plated in 96-well plates and grown in complete medium. The optical 
density values were expressed as relative cell viability. (B) ECs were infected, plated in 24-well plates and grown in complete medium. 
Cell number was evaluated by using a hemocytometer at the indicated time points. (C) Migration assay on infected HUVEC. Cells were 
grown in growth factor-depleted culture medium and plated in a Boyden chamber. Chemotaxis was stimulated with 10 ng/ml VEGF 
(Sigma-Aldrich). Migratory cells were stained and counted under a light microscope. (D and E) Wound healing assays of HUVEC infected 
as indicated. Cell monolayers were wounded with a sterile pipette tip, washed, and grown in complete medium. Cells were observed under 
a light microscope and photographed at 0 and 8 h. Representative experiments are shown (original magnification, x100). (F) HUVEC 
infected as indicated were grown in complete medium on Matrigel and the formation of capillary-like structures was observed 20 h after 
seeding. A representative experiment is shown (original magnification, ×100). (G) Quantification of tube length was performed based on the 
results shown in panel F. Results were expressed as means ± SD of four different fields randomly chosen from each group. All data represent 
the means ± SD of three-five independent experiments.
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or gelatin. Cell extracts were immunoprecipitated with 
anti-CD93 antibodies and immunoblotting analysis 
using anti-phosphotyrosine antibodies revealed CD93 
phosphorylation in cells spreading and growing on 
both substrates, even though CD93 phosphorylation 
levels were higher when cells were plated on laminin 
(Figure 4B). No CD93 phosphorylation was detected in 
cells plated in the absence of ECM components (data not 
shown). To investigate whether CD93 phosphorylation 
was due to DG engagement, ECs were silenced for 
DG and allowed to adhere and grow on laminin. DG 
knockdown caused a significant decrease of CD93 
phosphorylation compared to control ECs (Figure 4C), 
suggesting that CD93 is activated in a signaling pathway 
triggered by DG adhesion to the substrate. Since it 
has been observed that following cell adhesion β-DG 
undergoes tyrosine phosphorylation creating a SH2 
domain interaction site for the recruitment of active 
Src, which in turn phosphorylates other intracellular 
substrates [24, 25], we next examined the effect of PP2 
on CD93 phosphorylation in HUVEC plated on laminin. 
Immunoprecipitation analysis showed that the treatment 
with PP2 impaired CD93 phosphorylation (Figure 4D). 
Moreover, the constitutively active but not the kinase 
dead Src kinase was able to phosphorylate CD93 
(Figure 4E), indicating that Src can phosphorylate CD93. 
CD93 phosphorylation promotes EC adhesion 
and migration
To elucidate the role of CD93 phosphorylation 
during angiogenesis, we produced CD93 expressing clones 
resistant to silencing and mutated in tyrosine residues 
of the cytoplasmic domain. We generated four mutants: 
the shRNA rescue (res85), expressing CD93 resistant to 
silencing by shRNA clone 85; the shRNA rescue mutated 
in tyrosine 628 (res85Y1); the shRNA rescue mutated in 
tyrosine 644 (res85Y2); and the shRNA rescue mutated 
in both phosphorylation sites (res85Y1Y2). Lentiviral 
particles obtained from CD93 mutant clones were used 
to transduce each mutant into HUVEC, silenced for 
endogenous CD93 by expression of the shRNA clone  85. 
As shown in Figure 5A, Western blotting analyses revealed 
that in CD93-silenced cells each infection restored 
CD93 at the same expression levels as observed in cells 
expressing an unrelated shRNA, whereas endogenous 
CD93 was completely knocked down. Moreover, the 
increased β-DG expression, as a consequence of CD93 
depletion, was restored to control levels by expression of 
the CD93 mutants. In order to assess the role of CD93 
phosphorylation in EC adhesion, we first analyzed 
the effects of mutant expression in cells spreading 
onto laminin. Even though CD93 phosphorylation 
mutant expressing ECs showed no gross morphological 
modifications during spreading (Figure S6A), the adhesion 
of these cells were significantly decreased in comparison 
to control cells or cells expressing the shRNA rescue 
mutant (Figure S6B). Next, we investigated the ability of 
HUVEC to heal a wound when we replaced endogenous 
with tyrosine-mutated CD93. HUVEC silenced for CD93 
exhibited reduced migration, whereas the same cells 
expressing the shRNA rescue mutant restored their ability 
to fill the open gap. On the other hand, HUVEC expressing 
the phosphorylation mutants showed reduced migration 
similarly to CD93 silenced cells (Figure 5B). The altered 
migration phenotype was confirmed with a migration 
assay (Figure 5C). Further, HUVEC silenced for CD93 
showed reduced ability to form a capillary-like network, 
whereas the same cells expressing the shRNA rescue 
mutant restored this ability. Importantly, ECs expressing 
the phosphorylation mutants showed reduced in vitro tube 
formation similar to CD93 silenced cells, even though 
CD93 mutant in tyrosine 644 showed a weaker reduction 
in tube formation (Figure 5D and 5E).
CD93 signaling
By computational analysis we observed that tyrosine 
628 and 644 in the cytoplasmic domain of CD93 were 
contained in consensus sequences for the binding of the 
adapter protein Cbl (Figure 6A), which is recruited to target 
molecules through binding to tyrosine-phosphorylated 
sequences [26]. To verify the interaction between CD93 
and Cbl, we performed coimmunoprecipitation experiments 
from lysates of spreading ECs. Antibodies against CD93 
were able to coimmunoprecipitate Cbl from wild type 
cells (Figure 6B), whereas we did not observe this 
binding in β-DG-depleted cells (Figure 6C). Interestingly, 
coimmunoprecipitation analysis of CD93 mutants 
phosphorylated by Src kinase revealed that Cbl bound 
CD93 phosphorylated on tyrosine 628 and 644 (Figure 6D). 
Since tyrosine phosphorylation of Cbl has been shown 
to increase cell adhesion and spreading [27–29], we 
asked whether during EC adhesion Cbl was activated by 
phosphorylation. Western blotting analysis of EC lysates 
showed that during the spreading phase Cbl was strongly 
phosphorylated on tyrosine 774 (Figure 6E), while tyrosine 
700 and 731 of Cbl were not (data not shown). Moreover, 
double immunofluorescence staining and colocalization 
analyses of spreading ECs showed that CD93 significantly 
colocalized with tyrosine 774-phosphorylated Cbl at the cell 
margin (Figure 6F). To assess whether Cbl phosphorylation 
on tyrosine 774 was due to the presence of CD93, we 
analyzed by Western blotting CD93-silenced cells, which 
showed reduced Cbl phosphorylation on tyrosine 774 as 
compared to control cells (Figure 6G). Taken together, 
these results indicate that following cell adhesion through 
DG and CD93 phosphorylation on tyrosine residues 628 
and 644, CD93 binds to Cbl inducing phosphorylation on 
tyrosine 774 of Cbl.
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DISCUSSION
In this report, we describe the molecular interplay 
between CD93 and DG membrane proteins and highlight 
its importance in the improvement of EC adhesion and 
migration. Functional communication between distinct 
surface proteins has been formerly demonstrated and 
through their physical association and modulation of 
downstream effectors these molecules regulate cell 
physiology [17–19, 30]. We showed that CD93 and β-DG 
physically associated and that, following the imbalance 
caused by the absence of CD93, ECs overexpressed 
β-DG (and vice-versa) in an attempt to attain a normal 
physiological function, supporting a mechanism of close 
collaboration between CD93 and β-DG. Interestingly, the 
increased β-DG expression, as a consequence of CD93 
silencing, was restored to the levels of control cells by 
CD93 mutant expression, suggesting that physical CD93/
β-DG interaction is relevant for their balanced expression.
Our previous report has indicated that CD93 exerts 
its angiogenic function when ECs shuttle from a quiescent 
to a proliferating/migrating state [5]. Consistent with this 
observation, CD93 and also DG expression were found 
to be high in ECs of blood vessels inside cancerous in 
comparison to normal tissues [14, 31, 32], strengthening 
the complementary function of these proteins during 
formation of tumor vessels. Our study supports this 
concept of cooperation between CD93 and β-DG in the 
regulation of EC function during formation of new vessels. 
Indeed, by RNA interference technology, we observed that 
in ECs, CD93 or DG knockdown impaired to the same 
extent cellular physiologic and phenotypic characteristics, 
relevant to the angiogenic process.
The N-terminus of CD93 contains a C-type lectin-
like domain (CTLD) [4]. Despite the fact that a previous 
study has reported the identification of fibronectin, 
collagen I, and IV as specific ligands for the CTLD 
of endosialin and demonstrated its role as an adhesion 
molecule in the regulation of cell migration during 
angiogenesis [33], we did not observe any interaction 
between CD93 and common ECM proteins. Although 
we cannot exclude that CD93 might bind different 
ECM proteins, we suggest that CD93, through DG 
adhesion to the substrate, activates a signaling pathway 
involved in EC adhesion and migration. Consistent 
with this requirement, we observed that following DG 
adhesion to laminin CD93 was phosphorylated by Src. 
Importantly, Src is the same kinase responsible for β-DG 
phosphorylation in response to cell adhesion, generating 
a DG recruitment site for active Src itself [24]. 
Moreover, analyzing CD93 mutants in phosphorylation 
sites we observed that CD93 phosphotyrosine 628 
was predominantly instrumental for the stimulation 
of EC growth, adhesion and migration. This CD93 
Figure 4: Binding of DG to laminin induces CD93 phosphorylation via Src. (A) The schematic diagram illustrates the domains 
of CD93 and the 47-amino acid sequence of its cytoplasmic tail containing tyrosine 628 and 644. CTLD, C-type lectin-like domain; EGF-
like, Epidermal Growth Factor repeats; Mucin. Mucin-like domain; TM, transmembrane domain. (B) Cell extracts from ECs spreading 
and growing on gelatin or laminin were immunoprecipitated with anti-CD93 antibodies. Immunoprecipitates were analyzed by Western 
blotting with anti-phosphotyrosine and anti-CD93 antibodies to confirm equal loading. (C) HUVEC were infected with a lentiviral vector 
expressing unrelated (unr) or DG (clones C7 or C10) shRNAs. Not infected ECs were also analyzed (HUVEC). Cell extracts from cells 
spreading and growing on laminin were immunoprecipitated or not (+, −) with anti-CD93 antibodies and analyzed by Western blotting 
with anti-phosphotyrosine antibodies. To confirm equal loading, whole cell lysates were analyzed by Western blotting with anti-CD93 and 
anti-β-actin antibodies. (D) HUVEC were allowed to adhere and grow on laminin in the presence (+) or not (−) of PP2 (10 μm). Cell lysates 
were immunoprecipitated with anti-CD93 antibodies and analyzed by immunoblotting with anti-phosphotyrosine and anti-CD93 antibodies 
to confirm equal loading. In the same cell lysates, phosphorylation on tyrosine 416 of Src, a protein modification that is closely correlated 
with kinase activity, was analyzed by Western blotting with anti-phospho-Y416 Src and anti-Src antibodies to confirm equal loading. All 
experiments were performed three-four times. (E) Human Lenti-X 293T cells, which do not express wild type CD93, were transiently 
cotransfected with a construct expressing human CD93 and the constitutively active (DP) or kinase dead (DN) Src kinase. Transfection with 
an empty vector (mock) is indicated. Cell lysates were immunoprecipitated with anti-CD93 antibodies and analyzed by Western blotting 
with anti-phosphotyrosine and anti-CD93 antibodies to confirm equal loading.
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Figure 5: CD93 phosphorylation stimulates EC migration. HUVEC were infected with lentiviral particles expressing CD93 
shRNA clone 85 alone (85) or in combination (85+) with each CD93 mutant (res85, CD93 resistant to silencing; res85Y1, CD93 resistant 
to silencing mutated in tyrosine 628; res85Y2, CD93 resistant to silencing mutated in tyrosine 644; res85Y1Y2, CD93 resistant to silencing 
mutated in tyrosine 628 and 644). Control cells were infected with an unrelated shRNA (unr). (A) Cell extracts from infected ECs were 
analyzed by immunoblotting using anti-CD93, anti-β-DG, and anti-β-actin antibodies to confirm equal loading. (B) Wound healing assay 
of HUVEC infected as indicated. Cell monolayers were wounded with a sterile pipette tip, washed, and grown in complete medium. Cells 
were observed under a light microscope and photographed at 0 and 16 h. A representative experiment is shown (original magnification, 
×100). (C) Migration assay on infected HUVEC. Cells were grown in growth factor-depleted culture medium and plated in a Boyden 
chamber. Chemotaxis was stimulated with 10 ng/ml VEGF. Migratory cells were stained and counted under a light microscope. (D) ECs 
infected as indicated were grown in complete medium on Matrigel and the formation of vascular capillary networks was observed 20 h 
after seeding. A representative experiment is shown (original magnification, ×100). (E) Quantification of tube length was performed based 
on the results shown in panel D. Results were expressed as means ± SD of four different fields randomly chosen from each group. All data 
represent the means ± SD of three independent experiments. 
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Figure 6: During EC spreading, Cbl is recruited to CD93 and phosphorylated on tyrosine 774. (A) Sequence alignment of 
Cbl recruitment sites previously characterized in different signaling proteins. Colored as opposed to gray residues are generally conserved. 
Green residues are hydrophobic, blue residues basic, and violet residues polar. Three dots indicate that the protein sequence continues. 
EGFR, epithelial growth factor receptor; NTR, neurotrophin receptor; VEGFR, vascular endothelial growth factor receptor; APS, adapter 
with pleckstrin homology and SH2 domains; Lnk, lymphocyte adaptor protein. APS, Lnk, and SH2-B belong to a family of adapter proteins 
that are implicated in signaling transduction [26]. (B) HUVEC were released from culture plates by EDTA treatment, plated on laminin-
coated surface in complete medium, and allowed to spread. Cell lysates from spreading cells were immunoprecipitated with and without 
(No Ab) anti-CD93 antibodies. Immunoprecipitates were analyzed by Western blotting with anti-Cbl antibodies. Whole cell extracts were 
used to check the molecular size of the coimmunoprecipitated proteins (Cell ex.). Equal input was confirmed by Western blotting using 
anti-β-actin antibodies. (C) HUVEC were infected with a lentiviral vector expressing unrelated (unr) or DG (clones C7 or C10) shRNAs. 
Cell lysates were immunoprecipitated with anti-CD93 antibodies and analyzed by Western blotting with anti-Cbl and anti-CD93 antibodies 
to confirm equal loading. (D) Human Lenti-X 293T cells do not express wild type CD93 [5]. Cells were transiently cotransfected with 
constructs expressing CD93 mutants (res85, res85Y1, res85Y2, and res85Y1Y2) and the constitutively active (dominant positive, DP) 
or kinase dead (dominant negative, DN) Src kinase. Cell extracts were immunoprecipitated with anti-CD93 antibodies and analyzed by 
Western blotting with anti-Cbl, anti-phosphotyrosine, and anti-CD93 antibodies to confirm equal loading. In the presence of active Src, only 
wild type CD93 (res85) displays a phosphorylation signal and interacts with Cbl. (E) ECs were detached from culture plates and replated on 
laminin-coated surfaces. Cell extracts obtained at different degrees of cell spreading were analyzed by Western blotting using anti-phospho-
Cbl(Y774) antibodies. 15’ and 2 h indicate early and late spreading cells respectively. 24 h after replating, cells reached confluency. (F) ECs 
were fixed during the spreading phases and analyzed by immunofluorescence using anti-CD93 and anti-phospho-Cbl(Y774) antibodies. 
Overlay of stained cells and white dot colocalization images are shown. Plot shows quantification (using Manders’ coefficient) of CD93 
colocalization with phospho-Cbl(Y774) at the cell margin (c.m.) and in whole cells (w.c.) (mean ± SD; cells = 20; n = 3). Scale bar, 14 μm. 
In the inset white dots show CD93 and phospho-Cbl(Y774) colocalization at the cell margin. Scale bar of the inset is 3 μm. (G) HUVEC 
were infected with lentiviral vectors expressing unrelated (unr) or CD93 (clones 85 or 86) shRNAs. Lysates obtained from spreading cells 
were analyzed by Western blotting using anti-phospho-Cbl(Y774) antibodies. In E and G to confirm equal protein loading, whole cell 
lysates were analyzed by Western blotting with anti-Cbl and anti-β-actin antibodies. Every experiment was repeated at least three times.
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phosphotyrosine is located within a putative consensus 
motif for Cbl recognition. Cbl has been implicated in 
cell adhesion and organization of the actin cytoskeleton 
[29, 34], and its phosphorylation on tyrosine 774 
provides a docking site for downstream signaling 
components, such as CrkL, which in association to Cbl, 
has been shown to enhance cell migration [28, 34, 35]. 
In agreement with these observations, we showed that 
in ECs Cbl directly bound to phosphorylated CD93 and 
was phosphorylated only on tyrosine 774. In addition, 
this Cbl phosphotyrosine colocalized with CD93 
and was reduced in CD93-silenced cells, consistent 
with a role for CD93-dependent Cbl phosphorylation 
on tyrosine 774 in the enhancement of adhesion and 
migration. However, in the regulation of cytoskeletal 
phenomena Cbl can exert opposite effects following its 
interaction with the same protein by acting both as an 
adaptor and an E3 protein ligase [29, 34]. Interestingly, 
we observed that during cell spreading CD93 was 
ubiquitinated, but it was in a Cbl-independent manner 
(Figure S7), indicating that in this signaling pathway 
Cbl is mainly involved in the initial activation of 
a protein complex rather than in its subsequent 
inactivation.
Our study supports a model positing that CD93 
and DG cooperate in the promotion of EC adhesion and 
migration during angiogenesis. Although speculative, 
we provide a molecular mechanism of how CD93 and 
DG crosstalk. When ECs interact with laminin, DG is 
phosphorylated creating a binding site for the recruitment 
of active Src. Then Src phosphorylates CD93 leading to 
the recruitment of Cbl. Finally, Cbl is phosphorylated on 
tyrosine 774, activating a signaling pathway involved in EC 
adhesion and migration. Consistent with this model, in 
platelet cells Cbl phosphorylation on tyrosine 774 is involved 
in adhesion and spreading and is inhibited in the presence of 
PP2 [36]. Moreover, DG has been involved in the formation 
of activating protein complexes responsible for podosome 
formation and spreading of myoblasts [25, 30]. In conclusion, 
since angiogenesis is activated in several pathological 
conditions and a combination of antiendothelial drugs is an 
attractive therapeutic modality [37], our study, identifying a 
new signaling pathway based on the cooperation between 
CD93 and β-DG, may lead to the discovery of potential 
targets to be used in antiangiogenic therapy.
MATERIALS AND METHODS
DNA plasmids and constructs
The full-length cDNA of human DG (GenBank™ 
accession number NM_004393) was amplified using 
the BcaBEST™ RNA PCR kit (Takara Bio Inc., Otsu, 
Japan) from reverse transcription of total RNA extracted 
from HUVEC (oligonucleotides M479, 5′-GAGAA 
AGCTTGCCACCATGAGGATGTCTGTGG-3′ and M203, 
5′-GAGAGACTCGAGTTAAGGTGGGACATAGG-3′) and 
cloned in pcDNA3 cloning vector (Thermo Fisher Scientific, 
Waltham, MA, USA). The full-length cDNA of human 
CD93 was cloned as previously described [5]. For FRET 
analysis CD93 and DG full-length cDNA were subcloned 
into pEYFP-N1 and pECFP-N1 (Clontech Lab, Mountain 
View, CA, USA) vectors respectively, positioning the 
fluorescence tags at C terminal. The c-Src expression vectors 
were obtained as previously described [38]. The CD93 
mutants were obtained by using the QuickChange II XL Site-
Directed Mutagenesis kit (Agilent Technologies, Santa Clara, 
CA, USA) according to manufacturer’s instructions. Briefly, 
full-length cDNA of human CD93 was subcloned into pCCL 
retroviral vector [39]. The shRNA mutant (rescue) resistant 
to the clone 85 of CD93 shRNA was obtained by introducing 
a silent mutation in the shRNA recognition sequence by the 
exchange (TCT to AGC) of the serine codon 126. The CD93 
tyrosine (628 and 644) to phenylalanine substitutions were 
obtained by changing the codon sequences from TAC to 
TTC. All constructs were confirmed by sequencing.
2-DE and mass spectrometry
Cells were detached from culture plates by scraping 
in PBS containing EDTA, washed twice with ice-
cold PBS, resuspended in a buffer containing 65 mM 
DTE, 65 mM CHAPS, 9 M urea, 35 mM Tris-base, and 
disrupted by sonication in an ice bath. 60 µg of proteins/
sample were submitted to 2-DE as previously described 
[40]. Digitalized images were obtained by ImageScanner 
III and then qualitatively and quantitatively analyzed by 
the ImageMaster software (GE Healthcare BioSciences, 
Piscataway, NJ, USA). The increasing/decreasing 
index (fold change) was calculated as the ratio of spot 
relative volume between the different gel maps. Protein 
spot identification was obtained by MALDI-ToF/MS as 
previously described [41]. Mascot software v.2.2 (Matrix 
Science, Boston, MA, USA) was used to identify spots 
from the NCBI non-redundant database. Candidates with 
a score > 81 (corresponding to p ≥ 0.05 for a significant 
identification) were further evaluated by comparison with 
experimental coordinates from 2-DE.
Cell culture and transfection
HUVEC were isolated from umbilical cords 
collected from consenting healthy patients according to 
institutional guidelines. For each experiment at least three 
independent extractions of HUVEC were used. Cells 
were cultured on gelatin-coated Petri dishes as previously 
described [42]. Transient transfection experiments were 
performed by electroporation. Subconfluent cells were 
detached from the culture dish by trypsin treatment, 
washed, and resuspended in Ham’s F12 culture medium 
(Thermo Fisher Scientific) containing 2.5% fetal bovine 
serum at a concentration of 4 × 106 cells/cuvette with 
20 µg of plasmid DNA. Cells were electroporated with 
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one 0.15- ms pulse of 290 V (Gene Pulser II, Bio-Rad 
Laboratories, Hercules, CA, USA). After an additional 
incubation for 5 min at 37°C, cells were plated on 
appropriate culture dishes. Human Lenti-X 293T 
(Clontech Lab) and mouse BALB/c cell lines were 
cultured using standard conditions. In these cell lines 
transient transfection experiments were performed using 
Lipofectamine 2000 (Thermo Fisher Scientific) according 
to manufacturer’s instructions.
Immunofluorescence microscopy
Cells were seeded on glass coverslips, fixed in 
3% paraformaldehyde, and then treated as previously 
described [43]. The primary antibodies used were: mouse 
monoclonal anti-CD93 (mAb 4E1, 0.6 µg/µL [5]) 1:25, 
rabbit anti-β-DG (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA), and rabbit anti-phospho-Cbl (Y774) 
(Millipore, Billerica, MA, USA). Fluorescent images 
were captured using a Leica TCS SP2 laser-scanning 
confocal microscope. The quantitative colocalization 
analyses of CD93 and β-DG or phospho-Cbl signals were 
performed on optical sections captured at cell/substrate 
adhesion sites using ImageJ and the JACoP plug-in to 
determine Manders’ coefficient M1 [44], which represents 
the percentage of CD93 pixels that overlap β-DG or 
phospho-Cbl pixels. To show colocalization events by 
white dots, images were generated using ImageJ and the 
Colocalization plug-in.
Protein-protein interaction analyses
FRET acceptor photobleaching (apFRET) was 
carried out on fixed cells as previously described [45, 46]. 
Briefly, HUVEC transiently transfected and co-expressing 
β-DG-CFP and CD93-YFP were analyzed by using a 
40 mW argon laser line of 458 nm to excite β-DG-CFP 
(PMT window 465–505) and a line of 514 to excite CD93-
YFP (PMT window 525–590). Cells transfected with a 
single construct were used to calibrate laser intensity to 
prevent bleed-through. Acquisition parameters include 
image size of 512 × 512 pixels, 400Hz line scanning-rate, 
zoom 4x. In the photobleaching procedure, cells were 
bleached using a 514 nm laser beam at 100% intensity 
until the acceptor was photobleached down to about 10% 
of its initial value. The bleach time ranged from 2 to 5 
s. For each experiment, data were collected from 25–30 
different cells in different fields. For FRET analysis, 
we selected about half-cell as region of interest (ROI) 
and, after photobleaching, additional ROIs were chosen 
inside the photobleached area, which included both more 
discrete cell regions and an outside of the cell to use as 
background. FRET measurement was performed using 
the apFRET software (Leica Microsystems, Wetzlar, 
Germany), according to the manufacturer’s instructions.
The in situ interaction between CD93 and β-DG 
was detected by using the Duolink II detection kit 
(Olink Bioscience, Uppsala, Sweden) following the 
manufacturer’s instructions. Briefly, exponentially 
growing HUVEC were treated as for immunofluorescence 
microscopy by using mouse anti-CD93 and rabbit anti-β-
DG antibodies. Duolink secondary antibodies, provided 
as conjugates to oligonucleotides that are ligated together 
in a closed circle if the primary antibodies are in close 
proximity, were added. Polymerase amplification of any 
existing closed circles was performed and detection was 
achieved with complementary, fluorescently labeled 
oligonucleotides. Background was assayed by removing 
one of the two primary antibodies from the reaction. 
Fluorescent images were acquired under a confocal 
microscope at the focal plane of cell/ECM contact.
RNA interference-mediated knockdown of CD93 
and DG 
Silencing experiments were performed using 
retroviral vectors pLKO.1 from the TRC lentiviral 
shRNA library (Open Biosystems, Huntsville, AL, USA) 
expressing specific shRNAs for human CD93 [5], and DG 
(oligonucleotide TCRN0000056188, referred to as C7; 
and oligonucleotide TCRN0000056191, referred to as 
C10). Recombinant lentiviruses were produced and used 
for infection experiments as previously described [47].
Cell viability, adhesion, and motility assays
HUVEC viability and cell adhesion were evaluated 
as previously described [5]. For the wound healing 
assay, 1.5 × 105 HUVEC were seeded in a 24-well plate 
coated with gelatin and cultured for 24 hours. When cells 
reached the confluence, a straight scratch was created in 
the monolayer using a sterile pipette tip. Cultures were 
washed with PBS and grown in complete medium. 
Bright-field images were captured using an inverted 
microscope (Axiovert 200, Zeiss, Oberkochen, Germany) 
equipped with a Nikon DXM1200 digital camera. For 
each condition, images were acquired at three different 
positions along the scratch and a representative field was 
depicted. Chemotaxis analysis with Boyden transwell 
chambers and formation of capillary-like tube structures 
in Matrigel were performed as previously described [48].
Immunoprecipitation and immunoblotting 
analyses
Immunoprecipitation and immunoblotting exper-
iments were performed as previously described [49]. For 
co-immunoprecipitation experiments cells were lysed in 
Co-ip buffer (1% NP-40, 150 mM NaCl, 10 mM Tris-
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HCl pH 7.5, 1 mM EDTA, protease and phosphatase 
inhibitors, Sigma-Aldrich, St Louis, MO, USA). The 
following antibodies were used for immunoblotting: 
rabbit anti-CD93 (H190), mouse anti-phosphotyrosine, 
mouse anti-ubiquitin, and rabbit anti-β-DG (Santa Cruz 
Biotechnology); mouse anti-Cbl (Millipore); rabbit anti-
phospho-Cbl(Y731), rabbit anti-phospho-Y416 Src, and 
rabbit anti-Src 32G6 (Cell Signaling Tech., Danvers, 
MA, USA); rabbit anti-phospho-Cbl (Y700) (Abcam, 
Cambridge, UK); mouse anti-β-actin (Sigma-Aldrich). 
For immunoprecipitations, mouse anti-CD93 antibodies 
(mAb 4E1) were used coupled to Dynabeads Pan Mouse 
IgG (Thermo Fisher Scientific). The Src family tyrosine 
kinase inhibitor PP2 was purchased from Calbiochem 
(San Diego, CA, USA). 
Statistical analysis
All results are presented as means ± SD of at least 
three independent experiments. Statistical analysis was 
performed using Student’s t-test and values of p ≤ 0.05 
were considered statistically significant.   
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